Press Releases
 
    • JUNE 2014

      VDDI is pleased to announce that on June 2014 a CTA IND was filed with Chinese Food and Drug Administration for xemilofiban through the VDDI partner Heyuan Hebei, PRC.

      Xemilofiban application number
      API application number : CXHL1400496皖
      Injectable drug application number: CXHL1400497皖
      CFDA IND filling reference: HYC-11395

  • APRIL 20, 2004

    BIO Mid-America VentureForum
    Dr. Stephen Porter has been invited to speak at the BIO Mid-America VentureForum which is The Regional Venture Conference for the financial community and biotech companies in America’s Heartland. He is scheduled to speak on Tuesday, May 4th, at 10:00 AM. This conference is being held at the Chase Park Plaza Hotel in St. Louis, Missouri.
    For more information, please contact the hotel at 1-877-587-2427

  • APRIL 20, 2004

    6th Annual C21 BioVentures Conference
    Mr. Steve Sensoli has been invited to speak at the 6th Annual C21 BioVentures Conference on Wednesday, May 5th, at 2:30 PM, in Stream A. The mission of this conference is to educate in the bioscience industry the trends that are driving its growth and development in the 21st century and for leading investors and company executives to meet and exchange ideas and to review business plans of innovative new companies in the fields of biotechnology, informatics, medical devices and healthcare services. This conference is being held at the Paradise Point Resort and Spa in San Diego, California.
    For more information, please call 1-831-464-7105 or 1-831-464-4230

  • June 20, 2003 - Brentwood, TN
    VDDI garners $1.6 million grant for oral anthrax antibiotic. The Brentwood-based biopharmaceutical development firm says the funding will go toward developing a NADS inhibitor as an oral antibiotic for anthrax and other gram positive bacteria.
    (Click here for full article)
  • June 12 , 2003 - Brentwood, TN and Princeton, NJ
    VDDI Pharmaceuticals, a biopharmaceutical development company, today announced it has acquired a portfolio of patents and patent applications from Interlink Biotechnologies LLC (ILB) that will enable the successful implementation of medical peptides.
    (Click here for full article)
  • June 12, 2003 - Brentwood, TN and Birmingham, AL
    VDDI Pharmaceuticals, a biopharmaceutical development company, and the University of Alabama at Birmingham today announced receipt of allowance for a patent from the United States Patent and Trademark Office for a NADs inhibitor (nicotinamide adenine dinculeotide synthetase) to treat hospital acquired fungal infections.
    (Click here for full article)
  • February 13, 2003 - Kalamazoo, MI
    WMU Drug Development Pact Will Bring Tennessee Firm to Michigan.
    A Tennessee firm will develop and commercialize a recent Pharmacia Corp. drug patent donation to Western Michigan University, and the firm will join the growing cluster of life science companies to open research facilities in Kalamazoo.
    (Click here for full article)
  • February 12 , 2003 - Nashville, TN
    Tennessee Firm Taking Pharmacia Drug Candidate to Market.
    Officials from Brentwood-based VDDI Pharmaceuticals announced today that the company has been awarded exclusive worldwide license rights for Pharmacia drug candidate, Xemilofiban (xemi). (Click here for full article)
  • October 8, 2002 - Franklin, TN
    Cool Springs Life Sciences Center Groundbreaking.
    The Cool Springs Life Sciences Center will be home to research and development-focused operations for biotech, pharmaceutical and medical device companies and support services, providing companies within the same industry an environment of collaboration and shared resources.
    (click here for a fact sheet)
  • May 7, 2002 - Nashville Business Journal
    VDDI Pharmaceuticals teams with ILB on peptide development
    VDDI Pharmaceuticals of Brentwood has agreed to collaborate with a Princeton, N.J., firm in the development of peptides for use in humans and animals. As part of the agreement, VDDI Pharmaceuticals will have access to InterLink Biotechnologies' patents and information related to peptides, which can be used to make pharmaceuticals.
    (click here for full article)
  • May 7, 2002 - Princeton, N.J. & Brentwood, TN.--Business Wire
    InterLink Biotechnologies Announces Agreement with Virtual Drug Development for New Peptide Pharmaceuticals.
    InterLink Biotechnologies LLC (ILB) and VDDI Pharmaceuticals today announced a research and development collaboration for the development of certain peptides for medical uses in humans and animals. (click here for full article)
  • February 26, 2002 - Research Triangle Park, NC and Brentwood TN
    Paradigm Genetics, Inc. (Nasdaq: PDGM) and VDDI Pharmaceuticals today announced a research and development collaboration for the development of antibiotics for the treatment of gram-positive bacterial infections. Under the terms of the agreement, VDDI Pharmaceuticals will support Paradigm's research and development efforts, as well as pay potential royalties. In addition, Paradigm will have the option to make an unspecified equity investment in VDDI Pharmaceuticals; further specific financial details were not disclosed. (click here for full article)
 
  • January 2, 2002 - The Tennessean
    State industry fighting terrorism
    Porter's company, Virtual Drug Development Inc., hopes that within 36 to 48 months it can provide the U.S. military with an anthrax treatment that has fewer side effects than two primary treatments now in use — the antibiotic Cipro and a vaccine that is in short supply.
    (click here for full article)
 
  • June 23, 2001 - NashvillePost.com
    A Brentwood biotechnology firm awaiting a $23 million federal research grant expects to finish developing an anthrax antidote that could have a potential market of as much as $650 million. (click here for full article)
 
  • August 2, 2000 - Brentwood, TN
    A $135,590 U.S. Department of Health and Human Services grant will enable Virtual Drug Development Inc. to continue its search for an antibiotic treatment of the chemical weapon anthrax, U.S. Rep. Bart Gordon announced. (click here for full article)
 
  • October 11, 2000 - US House of Representatives Testimony
    VDDI Pharmaceuticals was formed in order to capitalize on the opportunity to develop early stage pharmaceuticals. The Company licenses attractive product development opportunities from academic institutions, biotech firms and pharmaceutical companies. (click here for full article)
 
Media